We are analyzing https://link.springer.com/article/10.1007/s10147-006-0663-5.

Title:
Combination of radiotherapy with EGFR antagonists for head and neck carcinoma | International Journal of Clinical Oncology
Description:
The introduction of biologically sound radiation fractionation regimens and combinations of radiotherapy with chemotherapy have gradually improved both the survival of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) and the prospect of organ preservation. Long-term follow-up, however, has shown that some of the radiation–chemotherapy combinations are associated with increased late toxicity. This observation, in conjunction with advances in tumor biology, has led to the launch of investigations into molecular markers and targets for therapeutic interventions. Research on the epidermal growth factor receptor (EGFR)-mediated signaling pathway has enriched our understanding of the biology of HNSCC, in terms of carcinogenesis and cellular processes governing tumor response to therapy. The finding that the addition of an antibody-based inhibitor of the EGFR pathway to radiotherapy significantly improves locoregional control and overall survival rates in patients with locally advanced HNSCC, without increasing radiation-induced toxicity, has resulted in the growing acceptance of such combined regimens as a frontline therapy option for locally advanced HNSCC. Because such therapy has benefited only an additional 10%-15% of patients, studies are being undertaken to identify markers and mechanisms of resistance to EGFR antagonists that are essential for the further refinement of therapy. Overall, preclinical and clinical studies on EGFR have validated the concept that selective tumor radiation sensitization can be achieved by modulating a specific perturbed signaling pathway, and these studies have increased the enthusiasm for developing and investigating other novel agents targeting other cellular processes.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

While many websites aim to make money, others are created to share knowledge or showcase creativity. People build websites for various reasons. This could be one of them. Link.springer.com has a revenue plan, but it's either invisible or we haven't found it.

Keywords {🔍}

google, scholar, pubmed, cas, cancer, article, growth, factor, receptor, epidermal, cell, neck, clin, head, oncol, res, carcinoma, squamous, egfr, patients, kinase, radiation, therapy, tyrosine, advanced, biol, radiotherapy, inhibitor, phase, signaling, human, tumor, cells, cetuximab, pathway, antibody, combination, locally, study, radiat, jco, clinical, asco, annual, meeting, proceedings, postmeeting, edition, activation, erbb,

Topics {✒️}

dc%2bd38%2fislsktw%3d%3d 10 small-molecule kinase inhibitor li pm harari small-cell lung cancer month download article/chapter transforming growth factor-alpha anti-egfr antibody c225 dc%2bd28xmvvyntq%3d%3d 10 dc%2bd28xntvsrug%3d%3d 10 dc%2bd3cxislaqsw%3d%3d 10 dc%2bd3sxptfghug%3d%3d 10 dc%2bd2cxnvvkksw%3d%3d 10 dc%2bd2cxovvkjtw%3d%3d 10 dc%2bd38xltvwluw%3d%3d 10 dc%2bd2mzotfalsq%3d%3d 10 combining anti-egfr antibody dual-agent molecular targeting dna-dependent protein kinase irreversible pan-erb inhibitor growth factor receptor concurrent chemotherapy/radiation therapy/gefitinib tyrosine kinase inhibitor mitogen-activated protein dna double-strand breaks zeng dj tweardy increasing radiation-induced toxicity growth factor signaling anti-egfr therapies kalyankrishna jr grandis endothelial cell therapy radiation-induced enhanced proliferation yu pm weinberger article international journal monoclonal antibody cetuximab antibody-based inhibitor shia ne kemeny baselga jm trigo thomas aqz wentzel sordella dw bell neck cancer growth huang ea armstrong dyaf387otl2qtw%3d%3d 10 dyaf28xks1wmug%3d%3d 10 dyak28visvchuw%3d%3d 10 dyak287mtvektw%3d%3d 10 full article pdf liang kk ang nasu kk ang kinase signaling cascade goldman rb levy

Questions {❓}

(2003) An open-and-shut case?
(2006) Selecting lung cancer patients for treatment with epidermal growth factor receptor tyrosine kinase inhibitors by immunohistochemistry and fluorescence in situ hybridization – why, when, and how?
L Saltz (2005) Epidermal growth factor receptor-negative colorectal cancer: is there truly such an entity?
What did we learn?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Combination of radiotherapy with EGFR antagonists for head and neck carcinoma
         description:The introduction of biologically sound radiation fractionation regimens and combinations of radiotherapy with chemotherapy have gradually improved both the survival of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) and the prospect of organ preservation. Long-term follow-up, however, has shown that some of the radiation–chemotherapy combinations are associated with increased late toxicity. This observation, in conjunction with advances in tumor biology, has led to the launch of investigations into molecular markers and targets for therapeutic interventions. Research on the epidermal growth factor receptor (EGFR)-mediated signaling pathway has enriched our understanding of the biology of HNSCC, in terms of carcinogenesis and cellular processes governing tumor response to therapy. The finding that the addition of an antibody-based inhibitor of the EGFR pathway to radiotherapy significantly improves locoregional control and overall survival rates in patients with locally advanced HNSCC, without increasing radiation-induced toxicity, has resulted in the growing acceptance of such combined regimens as a frontline therapy option for locally advanced HNSCC. Because such therapy has benefited only an additional 10%-15% of patients, studies are being undertaken to identify markers and mechanisms of resistance to EGFR antagonists that are essential for the further refinement of therapy. Overall, preclinical and clinical studies on EGFR have validated the concept that selective tumor radiation sensitization can be achieved by modulating a specific perturbed signaling pathway, and these studies have increased the enthusiasm for developing and investigating other novel agents targeting other cellular processes.
         datePublished:2007-04-27T00:00:00Z
         dateModified:2007-04-27T00:00:00Z
         pageStart:99
         pageEnd:110
         sameAs:https://doi.org/10.1007/s10147-006-0663-5
         keywords:
            Radiotherapy
            Targeted therapy
            Epidermal growth factor receptor (EGFR)
            Predictive molecular markers
            Resistance
            Angiogenesis
            Oncology
            Surgical Oncology
            Cancer Research
         image:
         isPartOf:
            name:International Journal of Clinical Oncology
            issn:
               1437-7772
               1341-9625
            volumeNumber:12
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Juliette Thariat
               affiliation:
                     name:University of Texas M.D. Anderson Cancer Center
                     address:
                        name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Gokcen Yildirim
               affiliation:
                     name:University of Texas M. D. Anderson Cancer Center
                     address:
                        name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Kathryn A. Mason
               affiliation:
                     name:University of Texas M.D. Anderson Cancer Center
                     address:
                        name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Adam S. Garden
               affiliation:
                     name:University of Texas M. D. Anderson Cancer Center
                     address:
                        name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Luka Milas
               affiliation:
                     name:University of Texas M.D. Anderson Cancer Center
                     address:
                        name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:K. Kian Ang
               affiliation:
                     name:University of Texas M. D. Anderson Cancer Center
                     address:
                        name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Combination of radiotherapy with EGFR antagonists for head and neck carcinoma
      description:The introduction of biologically sound radiation fractionation regimens and combinations of radiotherapy with chemotherapy have gradually improved both the survival of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) and the prospect of organ preservation. Long-term follow-up, however, has shown that some of the radiation–chemotherapy combinations are associated with increased late toxicity. This observation, in conjunction with advances in tumor biology, has led to the launch of investigations into molecular markers and targets for therapeutic interventions. Research on the epidermal growth factor receptor (EGFR)-mediated signaling pathway has enriched our understanding of the biology of HNSCC, in terms of carcinogenesis and cellular processes governing tumor response to therapy. The finding that the addition of an antibody-based inhibitor of the EGFR pathway to radiotherapy significantly improves locoregional control and overall survival rates in patients with locally advanced HNSCC, without increasing radiation-induced toxicity, has resulted in the growing acceptance of such combined regimens as a frontline therapy option for locally advanced HNSCC. Because such therapy has benefited only an additional 10%-15% of patients, studies are being undertaken to identify markers and mechanisms of resistance to EGFR antagonists that are essential for the further refinement of therapy. Overall, preclinical and clinical studies on EGFR have validated the concept that selective tumor radiation sensitization can be achieved by modulating a specific perturbed signaling pathway, and these studies have increased the enthusiasm for developing and investigating other novel agents targeting other cellular processes.
      datePublished:2007-04-27T00:00:00Z
      dateModified:2007-04-27T00:00:00Z
      pageStart:99
      pageEnd:110
      sameAs:https://doi.org/10.1007/s10147-006-0663-5
      keywords:
         Radiotherapy
         Targeted therapy
         Epidermal growth factor receptor (EGFR)
         Predictive molecular markers
         Resistance
         Angiogenesis
         Oncology
         Surgical Oncology
         Cancer Research
      image:
      isPartOf:
         name:International Journal of Clinical Oncology
         issn:
            1437-7772
            1341-9625
         volumeNumber:12
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Juliette Thariat
            affiliation:
                  name:University of Texas M.D. Anderson Cancer Center
                  address:
                     name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Gokcen Yildirim
            affiliation:
                  name:University of Texas M. D. Anderson Cancer Center
                  address:
                     name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Kathryn A. Mason
            affiliation:
                  name:University of Texas M.D. Anderson Cancer Center
                  address:
                     name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Adam S. Garden
            affiliation:
                  name:University of Texas M. D. Anderson Cancer Center
                  address:
                     name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Luka Milas
            affiliation:
                  name:University of Texas M.D. Anderson Cancer Center
                  address:
                     name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:K. Kian Ang
            affiliation:
                  name:University of Texas M. D. Anderson Cancer Center
                  address:
                     name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:International Journal of Clinical Oncology
      issn:
         1437-7772
         1341-9625
      volumeNumber:12
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:University of Texas M.D. Anderson Cancer Center
      address:
         name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:University of Texas M. D. Anderson Cancer Center
      address:
         name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:University of Texas M.D. Anderson Cancer Center
      address:
         name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:University of Texas M. D. Anderson Cancer Center
      address:
         name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:University of Texas M.D. Anderson Cancer Center
      address:
         name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
         type:PostalAddress
      name:University of Texas M. D. Anderson Cancer Center
      address:
         name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Juliette Thariat
      affiliation:
            name:University of Texas M.D. Anderson Cancer Center
            address:
               name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:Gokcen Yildirim
      affiliation:
            name:University of Texas M. D. Anderson Cancer Center
            address:
               name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:Kathryn A. Mason
      affiliation:
            name:University of Texas M.D. Anderson Cancer Center
            address:
               name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:Adam S. Garden
      affiliation:
            name:University of Texas M. D. Anderson Cancer Center
            address:
               name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:Luka Milas
      affiliation:
            name:University of Texas M.D. Anderson Cancer Center
            address:
               name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      name:K. Kian Ang
      affiliation:
            name:University of Texas M. D. Anderson Cancer Center
            address:
               name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
      name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
      name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
      name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
      name:Department of Experimental Radiation Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA
      name:Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(398)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

4.75s.

LINK . SPRINGER . COM {}